Evidence map›Paper›PMID 26374685›Full record

ArticleClinical trials (London, England)2015

Oversight on the borderline: Quality improvement and pragmatic research.

Jonathan A Finkelstein, Andrew L Brickman, Alexander Capron, Daniel E Ford, Adrijana Gombosev, Sarah M Greene, R Peter Iafrate, Laura Kolaczkowski, Sarah C Pallin, Mark J Pletcher and 3 more

Open access · greenAbstract read
In one paragraph

Article in Clinical trials (London, England), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
18.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 70 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Consent Requirements for Testing Health Policies: An Intercontinental Comparison of Expert Opinions.Journal of empirical research on human research ethics : JERHRE · 2022
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Quality improvement into practice.BMJ (Clinical research ed.) · 2020
    Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 12 institutions in 1 country.

Jonathan A FinkelsteinDivision of General Pediatrics, Boston Children's Hospital, Departments of Pediatrics and Population Medicine, Harvard Medical School, Boston, MA, USA Jonathan.finkelstein@childrens.harvard.edu.
Andrew L BrickmanHealth Choice Network, Miami, FL, USA.
Alexander CapronGould School of Law and Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.
Daniel E FordJohns Hopkins School of Medicine, Baltimore, MD, USA.
Adrijana GombosevSchool of Medicine, University of California, Irvine, Irvine, CA, USA.
Sarah M GreenePatient-Centered Outcomes Research Institute, Washington, DC, USA.
R Peter IafrateUniversity of Florida, Gainesville, FL, USA.
Laura KolaczkowskiMultiple Sclerosis Patient-Powered Research Network, University of Dayton, Dayton, OH, USA.
Sarah C PallinLouisiana Public Health Institute, New Orleans, LA, USA.
Mark J PletcherUniversity of California, San Francisco, CA, USA.
Karen L StamanCHB Wordsmith, Inc., Raleigh, NC, USA.
Miguel A VazquezUniversity of Texas Southwestern Medical Center, Dallas, TX, USA.
Jeremy SugarmanJohns Hopkins Berman Institute of Bioethics, Baltimore, MD, USA.
Harvard University · USHealth Choice Network · USJohns Hopkins Berman Institute of Bioethics · USJohns Hopkins Medicine · USLouisiana Public Health Institute · USPatient-Centered Outcomes Research Institute · USThe University of Texas Southwestern Medical Center · USUniversity of California, Irvine · USUniversity of California, San Francisco · USUniversity of Dayton · USUniversity of Florida · USUniversity of Southern California · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
Health Care Systems Research Collaboratory SupplementU54AT007748 · NCCIH · DUKE UNIVERSITY · PI CURTIS, LESLEY H, HERNANDEZ, ADRIAN · 2012 to 2017
$15.1M
NCATS NIH HHS UL1 TR001079NCCIH NIH HHS U54 AT007748
6 · The paper itself

Abstract

Pragmatic research that compares interventions to improve the organization and delivery of health care may overlap, in both goals and methods, with quality improvement activities. When activities have attributes of both research and quality improvement, confusion often arises about what ethical oversight is, or should be, required. For routine quality improvement, in which the delivery of health care is modified in minor ways that create only minimal risks, oversight by local clinical or administrative leaders utilizing institutional policies may be sufficient. However, additional consideration should be given to activities that go beyond routine, local quality improvement to first determine whether such non-routine activities constitute research or quality improvement and, in either case, to ensure that independent oversight will occur. This should promote rigor, transparency, and protection of patients' and clinicians' rights, well-being, and privacy in all such activities. Specifically, we recommend that (1) health care organizations should have systematic policies and processes for designating activities as routine quality improvement, non-routine quality improvement, or quality improvement research and determining what oversight each will receive. (2) Health care organizations should have formal and explicit oversight processes for non-routine quality improvement activities that may include input from institutional quality improvement experts, health services researchers, administrators, clinicians, patient representatives, and those experienced in the ethics review of health care activities. (3) Quality improvement research requires review by an institutional review board; for such review to be effective, institutional review boards should develop particular expertise in assessing quality improvement research. (4) Stakeholders should be included in the review of non-routine quality improvement and quality improvement-related research proposals. Only by doing so will we optimally leverage both pragmatic research on health care delivery and local implementation through quality improvement as complementary activities for improving health.

Indexed as

Biomedical ResearchClinical Trials as TopicDelivery of Health CareEthics Committees, ResearchHumansQuality ImprovementResearch DesignUnited Statesethicshealth care operationspatient engagementpragmatic clinical trialsQuality improvementresearchstakeholder engagement

Identifiers

PMID26374685
PMCPMC4699562
OpenAlexW2098480500

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.